Altimmune (ALT) Change in Acquisitions & Divestments (2017 - 2026)

Altimmune (ALT) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $39.6 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 4.16% year-over-year to $39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.6 million (up 38.77% YoY) and the FY2025 annual result came in at $153.0 million, up 75.15% from the prior year.
• Change in Acquisitions & Divestments grew to $39.6 million in Q1 2026 per ALT's latest filing, from $9.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $105.5 million in Q2 2025 and bottomed at $9.4 million in Q4 2025.
• The 4-year median for Change in Acquisitions & Divestments is $26.4 million (2023), against an average of $31.9 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 441.28% in 2025, while the deepest fall reached 65.0% in 2025.
• Tracing ALT's Change in Acquisitions & Divestments over 4 years: stood at $25.9 million in 2023, then increased by 3.78% to $26.8 million in 2024, then slumped by 65.0% to $9.4 million in 2025, then soared by 321.65% to $39.6 million in 2026.
• Per Business Quant, the three latest ALT Change in Acquisitions & Divestments figures stand at $39.6 million (Q1 2026), $9.4 million (Q4 2025), and $105.5 million (Q2 2025).

Peer Comparison